AbbVie (ABBV) dropped 4.69% after FDA approved J&J’s Icotyde psoriasis pill, creating fresh competition for blockbuster drug Skyrizi.
The post AbbVie (ABBV) Shares Plunge Nearly 5% as FDA Clears J&J’s Rival Psoriasis Treatment appeared first on Blockonomi…
Read More















